NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $21.41 -0.49 (-2.24%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$21.28▼$21.8950-Day Range$19.60▼$25.0652-Week Range$18.91▼$31.81Volume73,489 shsAverage Volume184,526 shsMarket Capitalization$640.67 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Fulgent Genetics alerts: Email Address Fulgent Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside40.1% Upside$30.00 Price TargetShort InterestHealthy3.57% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$98,717 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.46) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.99 out of 5 starsMedical Sector144th out of 910 stocksMedical Laboratories Industry6th out of 18 stocks 3.0 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageFulgent Genetics has received no research coverage in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.57% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 0.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fulgent Genetics is -0.67. Previous Next 2.0 News and Social Media Coverage News SentimentFulgent Genetics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Fulgent Genetics this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows3 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,717.00 in company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to decrease in the coming year, from ($1.46) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulgent Genetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Fulgent Genetics Stock (NASDAQ:FLGT)Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Read More FLGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FLGT Stock News HeadlinesAugust 30, 2024 | insidertrades.comHanlin Gao Sells 563 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) StockAugust 30, 2024 | insidertrades.comJian Xie Sells 715 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) StockSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 31, 2024 | americanbankingnews.comMing Hsieh Sells 2,313 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) StockAugust 9, 2024 | investing.comFulgent Genetics (FLGT) Earnings Dates & ReportsAugust 3, 2024 | msn.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | fool.comFulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an IssueAugust 3, 2024 | seekingalpha.comFulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 2, 2024 | finance.yahoo.comFulgent Reports Second Quarter 2024 Financial ResultsAugust 2, 2024 | markets.businessinsider.comHere's what Wall Street expects from Fulgent Genetics's earnings reportJune 10, 2024 | globenewswire.comPress release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global MarketingJune 6, 2024 | seekingalpha.comFulgent Genetics: Growth Is ReturningJune 3, 2024 | businesswire.comFulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck CancerMay 24, 2024 | businesswire.comFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual MeetingMay 14, 2024 | businesswire.comMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsMay 6, 2024 | finance.yahoo.comFulgent Genetics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 4, 2024 | finance.yahoo.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call TranscriptSee More Headlines Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,184Year Founded2011Price Target and Rating Average Stock Price Target$30.00 High Stock Price Target$35.00 Low Stock Price Target$25.00 Potential Upside/Downside+40.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,820,000.00 Net Margins-56.22% Pretax Margin-56.32% Return on Equity-2.75% Return on Assets-2.53% Debt Debt-to-Equity RatioN/A Current Ratio5.27 Quick Ratio5.27 Sales & Book Value Annual Sales$290.71 million Price / Sales2.20 Cash Flow$3.09 per share Price / Cash Flow6.94 Book Value$37.26 per share Price / Book0.57Miscellaneous Outstanding Shares29,924,000Free Float20,420,000Market Cap$640.67 million OptionableOptionable Beta1.37 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Ming Hsieh (Age 68)Chairman & CEO Comp: $2.31MMr. Jian Xie (Age 58)COO & President Comp: $868.74kMr. Paul Kim (Age 57)Chief Financial Officer Comp: $879.61kDr. Hanlin Gao D.A.B.M.G. (Age 57)FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director Comp: $720.7kMs. Natalie PrescottGeneral Counsel & Chief Privacy OfficerMs. Doreen NgVP of Operations & Compliance and GM of Houston OfficeMr. Jakub SramVice President of Business Development & SalesMs. Ellen TsuiVice President of Human ResourcesMr. Brandon PerthuisChief Commercial OfficerDr. Lawrence M. Weiss M.D. (Age 67)Chief Medical Officer More ExecutivesKey CompetitorsGenetronNASDAQ:GTHAddus HomeCareNASDAQ:ADUSPrivia Health GroupNASDAQ:PRVABrightSpring Health ServicesNASDAQ:BTSGVeracyteNASDAQ:VCYTView All CompetitorsInsiders & InstitutionsHanlin GaoSold 563 sharesTotal: $12,853.29 ($22.83/share)Ming HsiehSold 2,313 sharesTotal: $52,805.79 ($22.83/share)Jian XieSold 715 sharesTotal: $16,323.45 ($22.83/share)Paul KimSold 733 sharesTotal: $16,734.39 ($22.83/share)Algert Global LLCBought 25,680 shares on 8/16/2024Ownership: 0.272%View All Insider TransactionsView All Institutional Transactions FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $28.91 on January 1st, 2024. Since then, FLGT shares have decreased by 25.9% and is now trading at $21.41. View the best growth stocks for 2024 here. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its earnings results on Friday, August, 2nd. The company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.45. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. Does Fulgent Genetics have any subsidiaries? Fulgent Genetics subsidiaries include Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Top institutional investors of Fulgent Genetics include Dimensional Fund Advisors LP (4.06%), Millennium Management LLC (3.20%), Divisadero Street Capital Management LP (1.69%) and Bank of New York Mellon Corp (0.67%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Jian Xie and Paul Kim. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ) and JD.com (JD). This page (NASDAQ:FLGT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.